Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic

TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder

• Follow our Australia news live blog for latest updates

• Get our breaking news email, free app or daily news podcast

Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness.

The Therapeutic Goods Administration’s (TGA) warning came after several GLP-1 RA medicines marketed in Australia as Ozempic, Wegovy and Mounjaro, among other products, were linked to 36 cases of the condition.